Ripertamab – DLBCL | HongKong DengYue Medicine

Ripertamab Application Scope

Ripertamab is a recombinant chimeric anti‑CD20 monoclonal antibody approved in China for B-cell non‑Hodgkin lymphoma.

Characteristics

• Ingredients: Ripertamab (also known as SCT-400)

• Properties:

  • Binds CD20 on B lymphocytes to induce complement-dependent cytotoxicity (CDC) 

  • Antibody-dependent cellular cytotoxicity (ADCC)

  • Designed for reduced immunogenicity in Chinese patients, with safety similar to rituximab

• Packaging Specification:

  • Supplied as an intravenous infusion solution

  • Dosing is typically 200 mg weekly x4

• Storage: Store vials refrigerated (2–8 °C); avoid light and freeze-thaw cycles

• Expiry Date: ​Refer to manufacturer’s label; typically valid 24 months from manufacture

• Executive Standard:

  • Complies with China NMPA biological drug standards

  • Sequence based on IgG1 allotype G1m(1,17)

• Approval Number: NMPA approval granted August 23, 2022, for CD20-positive DLBCL

• Date of Revision: Current prescribing info updated May 2025 per real-world study publications

• Manufacturer: Developed and produced by Sinocelltech Group Ltd. (China)

Guidelines for the Use of Ripertamab

• Dosage and Administration:

  • Standard regimen:

    • 200 mg IV infusion weekly for 4 weeks, aligned with R‑CHOP regimen protocols

  • Administer slowly with monitoring for infusion reactions

• Adverse Reactions:

  • Generally well tolerated

  • Most common: infusion-related reactions and mild cytopenias

  • No serious AEs reported in real-world PMN or DLBCL studies

• Contraindications:

  • Known hypersensitivity to ripertamab

  • Murine/human antibody components

  • Caution in patients with active infections due to B-cell depletion

• Precautions:

  • Monitor CBC and immunoglobulins during therapy

  • Pre-medicate per CD20 antibody protocols (e.g., antihistamine, acetaminophen)

  • Vigilance for hepatitis B reactivation—perform baseline screening

Ripertamab Interactions

• Drug Interactions:

  • No specific drug interactions are known

  • Avoid live vaccines during treatment

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.